首页 | 本学科首页   官方微博 | 高级检索  
     


Efficacy,tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2
Authors:Hans-Christoph Diener MD  PhD  Michael J. Marmura MD  Stewart J. Tepper MD  Robert Cowan MD  FAAN  Amaal J. Starling MD  Merle L. Diamond MD  Joe Hirman PhD  Lahar Mehta MD  Thomas Brevig MD  PhD  Bjørn Sperling MD  Roger Cady MD
Affiliation:1. Institute for Medical Informatics, Biometry and Epidemiology, Medical Faculty of the University of Duisburg-Essen, Essen, Germany;2. Jefferson Headache Center, Thomas Jefferson University Hospitals, Philadelphia, PA, USA;3. Department of Neurology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA;4. Department of Neurology and Neurological Sciences, Stanford University Headache and Facial Pain Program, Palo Alto, CA, USA;5. Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA;6. Diamond Headache Clinic, Chicago, IL, USA;7. Pacific Northwest Statistical Consulting, Inc., Woodinville, WA, USA;8. Lundbeck Seattle BioPharmaceuticals, Inc., Bothell, WA, USA;9. H. Lundbeck A/S, Copenhagen, Denmark
Abstract:
Keywords:calcitonin gene-related peptide inhibitor  chronic migraine  eptinezumab  medication-overuse headache
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号